Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Porter

Hemoglobin

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Hemoglobin|December 17, 2009
Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell diseaseJohn B Porter
Hemoglobin|December 17, 2009
Deferasirox: an updateJohn B Porter
Hemoglobin|June 8, 2010
Which psychosocial factors are related to chelation adherence in thalassemia? A systematic reviewMichael Evangeli, Kulsoom Mughal, John B Porter
Hemoglobin|March 10, 2018
Psychological Factors Associated with Episodic Chelation Adherence in ThalassemiaJane Vosper, Michael Evangeli, John B Porter, et al.
Hemoglobin|February 9, 2016
Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical UpdateAmelia Oliveira, Dana Warcel, Nancy Huntley, et al.
Hemoglobin|December 10, 2008
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]John B Porter, Ali T Taher, Maria D Cappellini, et al.
Hemoglobin|January 6, 2012
Secondary erythrocytosis due to compound homozygosity, but not compound heterozygosity, for Hb Luton and α-thalassemia: a family studyDima El-Sharkawi, Chris Fisher, Sachin Khambadkone, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Hemoglobin|December 17, 2009
Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell diseaseJohn B Porter
Hemoglobin|December 17, 2009
Deferasirox: an updateJohn B Porter
Hemoglobin|June 8, 2010
Which psychosocial factors are related to chelation adherence in thalassemia? A systematic reviewMichael Evangeli, Kulsoom Mughal, John B Porter
Hemoglobin|March 10, 2018
Psychological Factors Associated with Episodic Chelation Adherence in ThalassemiaJane Vosper, Michael Evangeli, John B Porter, et al.
Hemoglobin|February 9, 2016
Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical UpdateAmelia Oliveira, Dana Warcel, Nancy Huntley, et al.
Hemoglobin|December 10, 2008
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]John B Porter, Ali T Taher, Maria D Cappellini, et al.
Hemoglobin|January 6, 2012
Secondary erythrocytosis due to compound homozygosity, but not compound heterozygosity, for Hb Luton and α-thalassemia: a family studyDima El-Sharkawi, Chris Fisher, Sachin Khambadkone, et al.
Pageof 1